Patients with stage IV NSCLC may qualify for first-line monotherapy with pembrolizumab, a programmed death receptor-1 (PD-1) inhibitor, when at least 50% of their tumor cells show expression of programmed death ligand-1 (PD-L1) [5, 6]. This evidence concerns the gene CD274 and neoplasm.